



vaccinated in the spring before exposure to natural field infection occurs at turnout or weaning.

A good immune response is reliant on the reaction of an immunogenic agent and a fully competent immune system.

Immunogenicity of the vaccine antigen will be reduced by poor storage or inappropriate administration. Immuno-competence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.

#### **4.5 Special precautions for use**

i) Special precautions for use in animals

Vaccinate only healthy animals.

Following vaccination, vaccinated stock should not be mixed with unvaccinated stock or allowed to graze on pastures recently used by unvaccinated stock until 2 weeks after the second dose of Bovilis Huskvac.

Note: For optimum benefit it is important that the calf is exposed to pasture carrying some infection after this time, as this low level exposure enhances the immunity induced by vaccination with Bovilis Huskvac.

ii) Special precautions to be taken by the person administering the veterinary medicinal product to animals

Wash hands after use.

#### **4.6 Adverse reactions (frequency and seriousness)**

Transient episodes of coughing may occur approximately 7 days after either dose of Bovilis Huskvac but these usually subside in a few days.

#### **4.7 Use during pregnancy, lactation or lay**

Pregnancy:

Can be used during pregnancy.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

To ensure residual effects of long-acting anthelmintics and endectocides or sustained release bolus preparations do not interfere with the development of immunity following lungworm vaccination, avoid vaccination during period of

their activity, and do not use until 14 days after the second dose of Bovilis Huskvac.

#### **4.9 Amounts to be administered and administration route**

Vaccinate healthy animals of 8 weeks of age and older.  
Shake bottle well immediately before use and administer the full dose (25 ml) orally.

##### **Vaccination regime**

###### Basic vaccination scheme

Two doses at a dosage interval of approximately 4 weeks.

###### Re-vaccination

Lungworm immunity is maintained from season to season by the exposure to lungworm larvae, which in most cases occurs from the grazing of normal pastures after vaccination. Under these conditions of exposure, re-vaccination is generally not required.

A single dose of Bovilis Huskvac prior to each season's turnout will boost immunity where such exposure has not occurred, e.g. extensive use of anthelmintics or if using reserved or clean pasture for a large part of the grazing season.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

No symptoms other than those detailed in section 4.6 were observed following administration of twice the recommended dose.

#### **4.11 Withdrawal Period**

Zero days.

### **5. PHARMACOLOGICAL or IMMUNOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Immunologicals for bovidae, Cattle, Live parasitic vaccines;

ATC Vet Code: QI02AN01.

The vaccine contains third stage larvae of *D. viviparus* irradiated to prevent further development, and stimulates active immunity against *D. viviparus* infection.

### **6. PHARMACEUTICAL PARTICULARS**

#### **6.1 List of excipients**

Sodium chloride  
Potassium chloride  
Sodium Phosphate, Dibasic, anhydrous  
Monobasic Potassium Phosphate  
Purified Water

## **6.2 Incompatibilities**

Do not mix with any other veterinary medicinal product.

## **6.3 Shelf-life**

Shelf-life of the veterinary medicinal product as packaged for sale: 90 days.

## **6.4 Special precautions for storage**

Store in a refrigerator (2 °C - 8 °C).  
Do not freeze.

## **6.5 Nature and composition of immediate packaging**

25 ml larval suspension in 30 ml glass hydrolytic class type III bottles, closed with a metal screwcap with a PEP faced inlay.  
Cardboard box containing 12 x 25 ml (1 dose) bottles.

## **6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials**

Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.

## **7. MARKETING AUTHORISATION HOLDER**

MSD Animal Health UK Limited  
Walton Manor  
Walton  
Milton Keynes  
Buckinghamshire  
MK7 7AJ

## **8. MARKETING AUTHORISATION NUMBER**


Vm 01708/4328

## **9. DATE OF THE FIRST AUTHORISATION**

23 September 2005

## **10. DATE OF REVISION OF THE TEXT**

June 2020



Revised: June 2020  
AN: 00192/2020

Approved: 02 June 2020